Evropska unija - francoščina - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - des sérums et immunoglobulines, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Švica - francoščina - Swissmedic (Swiss Agency for Therapeutic Products)

reckitt benckiser (switzerland) ag - natrii alginas, natrii hydrogenocarbonas, calcium carbonas - suspension zum einnehmen im beutel - natrii alginas 500 mg, natrii hydrogenocarbonas 267 mg, calcii carbonas 160 mg, carbomerum 974p, natrii hydroxidum ad ph, aqua purificata, aromatica (minze), saccharinum natricum, propylis parahydroxybenzoas 6 mg, e 218 40 mg, ad suspensionem pro 10 ml corresp. natrium 142.6 mg. - antacidum - synthetika

Švica - francoščina - Swissmedic (Swiss Agency for Therapeutic Products)

reckitt benckiser (switzerland) ag - natrii alginas, natrii hydrogenocarbonas, calcium carbonas - suspension buvable en bouteilles - natrii alginas 500 mg, natrii hydrogenocarbonas 267 mg, calcii carbonas 160 mg, carbomerum 974p, natrii hydroxidum ad ph, aqua purificata, menthae piperitae aetheroleum, saccharinum natricum, propylis parahydroxybenzoas 6 mg, e 218 40 mg, ad suspensionem pro 10 ml corresp. natrium 142.6 mg. - antacidum - synthetika